Brandes Investment Partners 13F: Adds $13M to Pfizer (PFE) Stake

Brandes Investment Partners Increases Pfizer Stake

Brandes Investment Partners expanded its holdings in Pfizer Inc. PFE during the period, according to a Form 13F filing with the U.S. Securities and Exchange Commission for the period ended May 15, 2026. The firm raised its stake by 5.5%, which translates to an addition of 478,043 shares. Because 13F filings look backward, this report captures positions held at that specific point in time and may not reflect current holdings today.

Position Details and Portfolio Value

Following this change, Brandes Investment Partners owned a total of 9,107,225 shares of the pharmaceutical company. The reported value of this stake stood at approximately $240.4 million, based on the cost basis details provided in the filing. This move aligns with the firm's active management style, where it frequently shifts weights across healthcare equities depending on valuation.

Stock Valuation and Market Context

Pfizer shares trade on the New York Stock Exchange. The company carries a forward P/E ratio of 9.6, offering insight into its expected earnings relative to its current share price. Market participants often weigh these valuation metrics against broader sector trends when tracking institutional accumulation patterns in large-cap drug manufacturers.

Recent Insider Activity

Several insiders acquired shares of Pfizer on June 26, 2026. Shantanu Narayen purchased 2,059 shares at a price of $24.29, totaling about $50,013. Cyrus Taraporevala bought 1,544 shares at the same price for a value of approximately $37,504. Joseph Echevarria acquired 1,904 shares for about $46,248, while James Quincey added 1,595 shares valued at roughly $38,743.

Wall Street Analyst Views

Wall Street firms have updated their outlooks on the stock through the autumn. On October 9, 2026, JP Morgan maintained a neutral rating and set a $30.00 price target. Cantor Fitzgerald kept a neutral rating on October 8, 2026, moving its target to $28.00. Scotiabank maintained a sector outperform rating on October 6, 2026, lifting its target to $33.00. HSBC retained a hold rating on September 10, 2026, with a $30.00 target, while Guggenheim kept a buy rating on August 7, 2026, at a $31.00 target.

Pfizer Business Overview

Pfizer Inc. discovers and delivers biopharmaceutical products globally across multiple segments, addressing areas such as internal medicine, vaccines, oncology, and rare diseases. The company engages in treatments ranging from cardiovascular care to specialized immunotherapies.

What to Watch at PFE

Investors tracking institutional moves in Pfizer will look toward upcoming SEC filings and the company's next earnings report scheduled for November 3, 2026. These updates will provide further clarity on how large asset managers adjust their healthcare weightings over the coming quarters.